The flavonoid myricitrin exhibits various pharmacological and physiological effects. However, studies on the effects of myricitrin on obesity are limited. We hypothesized that dietary myricitrin would attenuate the adiposity and metabolic dysfunction that occur in obesity. To test this hypothesis, mice were randomly fed a high-fat diet (HFD) or HFD supplemented with myricitrin for 16 weeks. Myricitrin significantly reduced white adipose tissue (WAT) mass, adipocyte size, and plasma leptin levels, and also attenuated dyslipidemia. These changes appeared to result from increased energy expenditure and activation of the carnitine acyltransferase (CPT) and β-oxidation in WAT. Expressions of the proinflammatory genes NF-κB, TLR2, MCP1, and TNF-α were also lower in the WAT of myricitrin-supplemented mice. Moreover, myricitrin markedly reduced hepatic triglyceride accumulation and plasma aspartate transaminase levels by increasing CPT activity and reducing fatty acid synthase activity in the liver. Myricitrin-supplemented mice also showed improved glucose tolerance, insulin sensitivity, and decreased hyperinsulinemia, along with decreased levels of circulating resistin. In conclusion, long-term consumption of a myricitrin-supplemented diet may effectively protect against HFD-induced obesity and related metabolic disorders.
Get full access to this article
View all access options for this article.
References
1.
HrubyA, HuFB: The epidemiology of obesity: A big picture. Pharmacoeconomics, 2015; 33:673–689.
2.
RosenED, SpiegelmanBM: What we talk about when we talk about fat. Cell, 2014; 156:20–44.
3.
JungUJ, ChoiMS: Obesity and its metabolic complications: The role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci, 2014; 15:6184–6223.
ShimosakiS, TsurunagaY, ItamuraH, NakamuraM: Anti-allergic effect of the flavonoid myricitrin from Myrica rubra leaf extracts in vitro and in vivo. Nat Prod Res, 2011; 25:374–380.
6.
ZhangB, ShenQ, ChenY, et al.: Myricitrin alleviates oxidative stress-induced inflammation and apoptosis and protects mice against diabetic cardiomyopathy. Sci Rep, 2017; 7:44239.
7.
SunJ, SunG, CuiX, MengX, QinM, SunX: Myricitrin protects against doxorubicin-induced cardiotoxicity by counteracting oxidative stress and inhibiting mitochondrial apoptosis via ERK/P53 pathway. Evid Based Complement Alternat Med, 2016; 2016: 6093783.
8.
Domitrović R RashedK, CvijanovićO, et al.: Myricitrin exhibits antioxidant, anti-inflammatory and antifibrotic activity in carbon tetrachloride-intoxicated mice. Chem Biol Interac, 2015; 230:21–29.
9.
SunGB, QinM, YeJX, et al.: Inhibitory effects of myricitrin on oxidative stress-induced endothelial damage and early atherosclerosis in ApoE −/− mice. Toxicol Appl Pharmacol, 2013; 271:114–126.
10.
YangZG, JiaLN, ShenY, OhmuraA, KitanakaS: Inhibitory effects of constituents from Euphorbia lunulata on differentiation of 3T3-L1 cells and nitric oxide production in RAW264.7 cells. Molecules, 2011; 16:8305–8318.
11.
WhitePA, CercatoLM, BatistaVS, et al.: Aqueous extract of Chrysobalanus icaco leaves, in lower doses, prevent fat gain in obese high-fat fed mice. J Ethnopharmacol, 2016; 179:92–100.
12.
ChangCJ, TzengTF, LiouSS, ChangYS, LiuIM: Myricetin increases hepatic peroxisome proliferator-activated receptor α protein expression and decreases plasma lipids and adiposity in rats. Evid Based Complement Alternat Med, 2012; 2012: 787152.
13.
ChoiHN, KangMJ, LeeSJ, KimJI: Ameliorative effect of myricetin on insulin resistance in mice fed a high-fat, high-sucrose diet. Nutr Res Pract, 2014; 8: 544–549.
14.
SuHM, FengLN, ZhengXD, ChenW: Myricetin protects against diet-induced obesity and ameliorates oxidative stress in C57BL/6 mice. J Zhejiang Univ Sci B, 2016; 17:437–446.
15.
XiaSF, LeGW, WangP, QiuYY, JiangYY, TangX: Regressive effect of myricetin on hepatic steatosis in mice fed a high-fat diet. Nutrients, 2016; 8:799.
16.
CollinsS, MartinTL, SurwitRS, RobidouxJ: Genetic vulnerability to diet-induced obesity in the C57BL/6J mouse: Physiological and molecular characteristics. Physiol Behav, 2004; 81:243–248.
17.
MokSY, LeeS: Identification of flavonoids and flavonoid rhamnosides from Rhododendron mucronulatum for albiflorum and their inhibitory activities against aldose reductase. Food Chem, 2013; 136:969–974.
18.
ChoiMS, ParkHJ, KimSR, KimDY, JungUJ: Long-term dietary supplementation with yerba mate ameliorates diet-induced obesity and metabolic disorders in mice by regulating energy expenditure and lipid metabolism. J Med Food, 2017; 20:1168–1175.
19.
FolchJ, LeesM, Sloane StanleyGH: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem, 1957; 226:497–509.
20.
HulcherFH, OlesonWH: Simplified spectrophotometric assay for microsomal 3-hydroxy-3-methylglutaryl CoA reductase by measurement of coenzyme A. J Lipid Res, 1973; 14:625–631.
21.
BradfordMM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 1976; 72:248–254.
22.
NepokroeffCM, LakshmananMR, PorterJW: Fatty acid synthase from rat liver. Methods Enzymol, 1975; 35:37–44.
23.
MarkwellMAK, MacGroartyEJ, BieberLL, TolbertNE: The subcellular distribution of carnitine acyltransferases in mammalian liver and kidney. J Biol Chem, 1973; 248:3426–3432.
24.
LazarowPB: Assay of peroxisomal β-oxidation of fatty acids. Methods Enzymol, 1981; 72:315–319.
25.
SchmittgenTD, LivakKJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protocol, 2008; 3:1101–1108.
26.
Jensen-UrstadAP, SemenkovichCF: Fatty acid synthase and liver triglyceride metabolism: Housekeeper or messenger?. Biochim Biophys Acta, 2012; 1821:747–753.
27.
WolfgangMJ, LaneMD: Control of energy homeostasis: Role of enzymes and intermediates of fatty acid metabolism in the central nervous system. Annu Rev Nutr, 2006; 26:23–44.
28.
HuM: Commentary: Bioavailability of flavonoids and polyphenols: Call to arms. Mol Pharm, 2007; 4:803–806.
29.
MaY, ZengM, SunR, HuM: Disposition of flavonoids impacts their efficacy and safety. Curr Drug Metabol, 2014; 15:841–864.
30.
DangY, LinG, XieY, DuanJ, MaP, LiG, JiG: Quantitative determination of myricetin in rat plasma by ultraperformance liquid chromatography tandem mass spectrometry and its absolute bioavailability. Drug Res (Stuttg), 2014; 64:516–522.
31.
Del RioD, BorgesG, CrozierA: Berry flavonoids and phenolics: Bioavailability and evidence of protective effects. Br J Nutr, 2010; 104:S67–S90.
32.
MatsukawaN, MatsumotoM, HaraH: Nondigestible saccharide enhances transcellular transport of myricetin glycosides in the small intestine of rats. A newly defined mechanism of flavonoid absorption. In: Dietary Fiber and Health (ChoS, AlmeidaN, eds.). New York: CRC Press, 2012, pp. 487–496.
33.
MaronpotRR, KoyanagiM, DavisJ, et al.: Safety assessment and single-dose toxicokinetics of the flavouring agent myricitrin in Sprague-Dawley rats. Food Addit Contam Part A Chem Anal Control Expo Risk Assess, 2015; 32:1799–1809.
34.
YokomizoA, MoriwakiM: Transepithelial permeability of myricitrin and its degradation by simulated digestion in human intestinal Caco-2 cell monolayer. Biosci Biotechnol Biochem, 2005; 69:1774–1776.
35.
YokomizoA, MoriwakiM: Myricitrin degraded by simulated digestion inhibits oxidation of human lowdensity lipoprotein. Biosci Biotechnol Biochem, 2005; 69:693–699.
36.
XiangD, WangCG, WangWQ, et al.: Gastrointestinal stability of dihydromyricetin, myricetin, and myricitrin: An in vitro investigation. Int J Food Sci Nutr, 2017; 68:704–711.
37.
TsengYH, CypessAM, KahnCR: Cellular bioenergetics as a target for obesity therapy. Nat Rev Drug Discov, 2010; 9:465–482.
38.
HarperRD, SaggersonED: Some aspects of fatty acid oxidation in isolated fat-cell mitochondria from rat. Biochem J, 1975; 152:485–494.
39.
BöttcherH, FürstP: Decreased white fat cell thermogenesis in obese individuals. Int J Obes Relat Metab Disord, 1997; 21:439–444.
40.
WangT, ZangY, LingW, CorkeyBE, GueW: Metabolic partitioning of endogenous fatty acid in adipocytes. Obes Res, 2003; 11:880–887.
41.
TorchonE, RayR, HulverMW, McMillanRP, VoyBH: Fasting rapidly increases fatty acid oxidation in white adipose tissue of young broiler chickens. Adipocyte, 2017; 6:33–39.
42.
RatnerC, MadsenAN, KristensenLV, et al.: Impaired oxidative capacity due to decreased CPT1b levels as a contributing factor to fat accumulation in obesity. Am J Physiol Regul Integr Comp Physiol, 2015; 308:R973–R982.
43.
MalandrinoMI, FuchoR, WeberM, et al.: Enhanced fatty acid oxidation in adipocytes and macrophages reduces lipid-induced triglyceride accumulation and inflammation. Am J Physiol Endocrinol Metab, 2015; 308:E756–E769.
44.
GaoX, LiK, HuiX, et al.: Carnitine palmitoyltransferase 1A prevents fatty acid-induced adipocyte dysfunction through suppression of c-Jun N-terminal kinase. Biochem J, 2011; 435:723–732.
45.
van der HeijdenRA, SheedfarF, MorrisonMC, et al.: High-fat diet induced obesity primes inflammation in adipose tissue prior to liver in C57BL/6j mice. Aging (Albany, NY), 2015; 7:256–268.
46.
HotamisligilGS, SpiegelmanBM: Tumor necrosis factor alpha: A key component of the obesity-diabetes link. Diabetes, 1994; 43:1271–1278.
47.
UysalKT, WiesbrockSM, MarinoMW, HotamisligilGS: Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature, 1997; 389:610–614.
48.
KandaH, TateyaS, TamoriY, et al.: MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest, 2006; 116:1494–1505.
49.
WeisbergSP, HunterD, HuberR, et al.: CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest, 2006; 116:115–124.
50.
CaamañoJ, HunterCA: NF-kappaB family of transcription factors: Central regulators of innate and adaptive immune functions. Clin Microbiol Rev, 2002; 15:414–429.
51.
KimSJ, ChoiY, ChoiYH, ParkT: Obesity activates Toll-like receptor-mediated proinflammatory signaling cascades in the adipose tissue of mice. J Nutr Biochem, 2012; 23:113–122.
52.
Al-SuhaimiEA, ShehzadA: Leptin, resistin and visfatin: The missing link between endocrine metabolic disorders and immunity. Eur J Med Res, 2013; 18:12.
53.
SchwimmerJB, DeutschR, KahenT, et al.: Prevalence of fatty liver in children and adolescents. Pediatrics, 2006; 118:1388–1393.
54.
BjörntorpP: “Portal” adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis, 1990; 10:493–496.
55.
LewisGF, CarpentierA, AdeliK, GiaccaA: Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev, 2002; 23:201–229.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
